Navigation Links
XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Date:6/30/2008

nt.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, the likelihood of successful results from a clinical trial with Bicifadine, operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 2b clinical trial with Bicifadine and obtain positive trial results from the Phase 2b clinical trial, all of which will directly impact our ability to continue to fund our operations; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2008. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... SANTA CLARA, Calif., Aug. 15, 2011 NewCardio, Inc., (OTC ... results for the second quarter ended June 30, 2011. More ... Quarterly Report on Form 10-Q, filed today with the Securities ... QTinno® was selected by a top 5 global pharmaceutical company ...
... Aug. 15, 2011 Millennium HealthCare ... KBL, LLP, a Public Company Accounting Oversight Board (PCAOB) ... KBL, LLP provides a combination of ... emerging businesses. Their professionals maintain an entrepreneurial spirit and ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8Millennium HealthCare Inc. Engages KBL, LLP 2
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... 24, 2014 Dental implants benefit millions ... tooth replacement. They offer the strongest and most secure ... other forms of tooth replacement. They will never slip ... adjacent teeth for support, and they prevent the jaw ... told that they are not suitable candidates for dental ...
(Date:12/24/2014)... Final Cut Pro X plugin ... Film Studios. , “The ProDenoise plugin that allows users to ... said Christina Austin, CEO of Pixel Film Studios. “ProDenoise is ... X editors toolbox.” , Final Cut Pro X users can ... footage with ProDenoise from Pixel Film Studios. ProDenoise can quickly ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... vaccine that U.S. officials are preparing to test in West ... vaccine produced a safe and potent immune response in Africans. ... more than 100 Ugandans in 2009 and 2010, prompted the ... protect a person against infection by Ebola, said study author ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... new study shows exercise may allow for better brain ... mentally engaged.// ,Researchers from the Oregon Health and ... causes physical changes in the brain. Researchers say they ... want environmental factors such as smoking, drinking, and obesity ...
... new study shows a novel new drug is beneficial ... cells and is the first in a new class ... ,The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or ... the treatment of rheumatoid arthritis. Researchers from Belgium conducted ...
... shows bone marrow stem cells may help restore damaged ... the American Heart //Association’s Scientific Sessions 2003 presented their ... that took place in 2001. Results from that trial ... his own bone marrow had improved heart function. ...
... say women will now have to talk seriously with their ... ,Pancreatic cancer affects only 31,000 Americans a year, but it ... study of 88,000 nurses found that those who took two ... had a 58 percent higher risk of pancreatic cancer.,Researchers expected ...
... A new study shows the symptoms women experience before ... the symptoms they expect to experience. ,Researchers interviewed ... and were discharged from five different medical sites. The ... asked the women to identify their symptoms before their ...
... new study shows children who are obese are more ... not overweight. ,Researchers from the University of Michigan studied ... The children and their parents took part in the ... weight, behavior, physical and mental health, education, demographic, and ...
Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... is a comprehensive vital sign monitor. , ,Adult, ... products for efficiency in patient care., ,Standard Functions: ... - Temp - Multi-gas Sensor (HAL, ENF, ISO, ... ,Optional Functions: ,5-Lead ECG - FiO 2 - ...
... CS makes the outstanding ... CS even more flexible. ... Technologies, the Wireless Propaq ... ethernet Local Area Networks ...
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: